On Invalid Date, Blueprint Medicines (NASDAQ: BPMC) reported Q4 2023 earnings per share (EPS) of -$1.82, up 31.32% year over year. Total Blueprint Medicines earnings for the quarter were -$110.92 million. In the same quarter last year, Blueprint Medicines's earnings per share (EPS) was -$2.65.
As of Q2 2024, Blueprint Medicines's earnings has grown year over year. Blueprint Medicines's earnings in the past year totalled -$506.98 million.
What is BPMC's earnings date?
Blueprint Medicines's earnings date is Invalid Date. Add BPMC to your watchlist to be reminded of BPMC's next earnings announcement.
What was BPMC's revenue last quarter?
On Invalid Date, Blueprint Medicines (NASDAQ: BPMC) reported Q4 2023 revenue of $71.96 million up 85.55% year over year. In the same quarter last year, Blueprint Medicines's revenue was $38.78 million.
What was BPMC's revenue growth in the past year?
As of Q2 2024, Blueprint Medicines's revenue has grown 22.22% year over year. This is 122.41 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Blueprint Medicines's revenue in the past year totalled $249.38 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.